Multidisciplinary Treatment With Repeated Thermal Ablation for Multisite Metastatic Colon Cancer in an Elderly Patient.

Anticancer ResOct 1, 2026
Case ReportOncology (Medical)Geriatrics

Taishi Yamane, Toshiro Masuda, Yasunori Nagayama et al.

✦ AI-curated · Sources linked

Case in brief

An 81-year-old woman with a history of myocardial and cerebral infarctions presented with metastatic colon cancer, including multiple liver and ovarian metastases. After initial chemotherapy and surgeries, her performance status declined, leading her to decline further chemotherapy. She underwent percutaneous thermal ablation for recurrent liver and lung metastases. Five years post-treatment initiation, she remains disease-free.

Diagnostic / clinical pearl

This case highlights the potential of repeated thermal ablation as a viable treatment option for elderly patients with metastatic colon cancer who are unfit for chemotherapy or major surgery.

Source

PubMed · PMID 42823149

Published in Anticancer Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.